AU2009323854B2 - Antibacterial compounds - Google Patents

Antibacterial compounds Download PDF

Info

Publication number
AU2009323854B2
AU2009323854B2 AU2009323854A AU2009323854A AU2009323854B2 AU 2009323854 B2 AU2009323854 B2 AU 2009323854B2 AU 2009323854 A AU2009323854 A AU 2009323854A AU 2009323854 A AU2009323854 A AU 2009323854A AU 2009323854 B2 AU2009323854 B2 AU 2009323854B2
Authority
AU
Australia
Prior art keywords
compound
alkyl
compounds
halo
bibenzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009323854A
Other languages
English (en)
Other versions
AU2009323854A2 (en
AU2009323854A1 (en
Inventor
Paul James Davis
Olivier De Moor
Colin Richard Dorgan
Peter David Johnson
Alan Geoffrey Roach
Richard Storer
Richard Vickers
Francis Xavier Wilson
Graham Michael Wynne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SUMMIT (OXFORD) Ltd
Original Assignee
Summit Oxford Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Oxford Ltd filed Critical Summit Oxford Ltd
Publication of AU2009323854A1 publication Critical patent/AU2009323854A1/en
Publication of AU2009323854A2 publication Critical patent/AU2009323854A2/en
Application granted granted Critical
Publication of AU2009323854B2 publication Critical patent/AU2009323854B2/en
Assigned to SUMMIT (OXFORD) LIMITED reassignment SUMMIT (OXFORD) LIMITED Request for Assignment Assignors: SUMMIT CORPORATION PLC
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
AU2009323854A 2008-12-02 2009-12-01 Antibacterial compounds Active AU2009323854B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0821913.1 2008-12-02
GBGB0821913.1A GB0821913D0 (en) 2008-12-02 2008-12-02 Antibacterial compounds
PCT/GB2009/002792 WO2010063996A2 (en) 2008-12-02 2009-12-01 Antibacterial compounds

Publications (3)

Publication Number Publication Date
AU2009323854A1 AU2009323854A1 (en) 2010-06-10
AU2009323854A2 AU2009323854A2 (en) 2011-06-30
AU2009323854B2 true AU2009323854B2 (en) 2014-06-26

Family

ID=40262471

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009323854A Active AU2009323854B2 (en) 2008-12-02 2009-12-01 Antibacterial compounds

Country Status (27)

Country Link
US (3) US8975416B2 (enExample)
EP (3) EP3095783A1 (enExample)
JP (3) JP5665756B2 (enExample)
KR (1) KR101643435B1 (enExample)
CN (1) CN102227411B (enExample)
AU (1) AU2009323854B2 (enExample)
BR (2) BRPI0922220B8 (enExample)
CA (1) CA2744962C (enExample)
CY (2) CY1116383T1 (enExample)
DK (2) DK2373631T3 (enExample)
ES (2) ES2575908T3 (enExample)
GB (1) GB0821913D0 (enExample)
HR (2) HRP20150518T1 (enExample)
HU (1) HUE029151T2 (enExample)
IL (1) IL213325A (enExample)
LT (1) LT2907813T (enExample)
MX (1) MX2011005837A (enExample)
NZ (1) NZ593111A (enExample)
PL (2) PL2907813T3 (enExample)
PT (2) PT2373631E (enExample)
RS (1) RS54904B1 (enExample)
RU (1) RU2525915C2 (enExample)
SG (1) SG171939A1 (enExample)
SI (2) SI2907813T1 (enExample)
SM (2) SMT201500117B (enExample)
WO (1) WO2010063996A2 (enExample)
ZA (1) ZA201103751B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
WO2011151619A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
GB2480813A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
WO2011151620A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
GB2480814A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
WO2011151621A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
GB2480816A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of Clostridium difficile associated diseases
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
CN104955466A (zh) 2012-11-23 2015-09-30 赛里斯治疗公司 协同细菌组合物和其制造方法和用途
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
KR102222273B1 (ko) 2013-02-04 2021-03-08 세레스 테라퓨틱스, 인코포레이티드 조성물 및 방법
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
WO2014145958A2 (en) 2013-03-15 2014-09-18 Seres Health, Inc. Network-based microbial compositions and methods
EP3074027B1 (en) 2013-11-25 2024-12-18 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP3082431A4 (en) 2013-12-16 2017-11-15 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
JP6526956B2 (ja) * 2013-12-19 2019-06-05 花王株式会社 固形状組成物
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
US20180000793A1 (en) * 2015-02-06 2018-01-04 Ernesto Abel-Santos Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis
BR112020002992A2 (pt) 2017-08-14 2020-08-18 Seres Therapeutics, Inc. composições e métodos para tratamento de doença colestática
EP3692030B1 (en) 2017-10-05 2023-04-19 Sandoz AG Process for the preparation of ridinilazole using acid addition salts
CA3080586A1 (en) 2017-10-30 2019-05-09 Seres Therapeutics, Inc. Compositions and methods for treating antibiotic resistance
JP7730803B2 (ja) * 2019-07-17 2025-08-28 サミット （オックスフォード） リミティド リジニラゾールの調製方法およびその結晶形態
PH12022551379A1 (en) 2019-12-06 2023-05-03 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
US20210324009A1 (en) * 2020-04-17 2021-10-21 The University Of Hong Kong Anti-bacterial calcium-dependent antibiotic (cda) analogs and methods of treating bacterial infections
GB202100470D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole
GB202100471D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Preparation of antibacterial compounds
CA3221564A1 (en) * 2021-05-24 2022-12-01 Aimmax Therapeutics, Inc. Pristinamycin ia and flopristin combinations in treating or preventing bacterial infections
DK4347031T3 (da) 2021-06-04 2025-12-01 Vertex Pharma N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler
PE20250155A1 (es) 2021-06-14 2025-01-22 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cancer
EP4398890A4 (en) 2021-09-09 2025-07-30 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The Univ Of Nevada Las Ve C. Difficile Spore Germination Inhibitors
WO2024112631A1 (en) * 2022-11-22 2024-05-30 Aimmax Therapeutics, Inc. Streptogramin a monotherapy for treating or preventing bacterial infections
EP4418810A1 (de) 2023-02-15 2024-08-21 Siemens Aktiengesellschaft Verfahren zur rechnergestützten überwachung einer industriellen anlage mittels eines funknetzes

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3661849A (en) * 1965-10-06 1972-05-09 Ashland Oil Inc Heterocyclic polyimides prepared from heterocyclic diamines
JPS50154250A (enExample) * 1974-05-31 1975-12-12
US4087409A (en) * 1966-11-07 1978-05-02 Monsanto Company Ordered heterocyclic copolymers
US5317078A (en) * 1991-10-30 1994-05-31 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Polybenzimidazole via aromatic nucleophilic displacement
US5824698A (en) * 1994-11-17 1998-10-20 Hoffman-La Roche Inc. Antibacterial dibenzimidazole derivatives
WO2002060374A2 (en) * 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Benz-1,3-azole derivatives and their uses as heparanase inhibitors
WO2003007955A2 (en) * 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
EP1547996A1 (en) * 2002-08-30 2005-06-29 BF Research Institute, Inc. Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3503929A (en) * 1965-10-21 1970-03-31 Minnesota Mining & Mfg Polyimidazoquinazolines and polyamidobenzimidazoles
DE1670684A1 (de) 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
JPS50140445A (enExample) * 1974-04-30 1975-11-11
US5089592A (en) 1988-06-09 1992-02-18 The Dow Chemical Company Biscyclobutarene monomer comprising two cyclobutarene moieties bridged by a divalent radical comprising at least one benzothiazole or benzimidazole linkage
JPH03500661A (ja) * 1988-06-09 1991-02-14 ザ・ダウ・ケミカル・カンパニー ベンゾキサゾール，ベンゾチアゾールまたはベンズイミダゾールの少なくとも１つの結合によって架橋したビスシクロブタレンのモノマー，オリゴマー及びポリマー
GB9108279D0 (en) * 1991-04-18 1991-06-05 Ucb Sa A method of preparing 1h-benzimidazoles
CN1164227A (zh) * 1994-11-17 1997-11-05 弗·哈夫曼-拉罗切有限公司 联苯并咪唑衍生物
US5770617A (en) 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
JPH11158156A (ja) 1997-12-03 1999-06-15 Earth Chem Corp Ltd 新規な１−（４−アルキルオキシフェニル）イミダゾール化合物
JPH11158158A (ja) * 1997-12-03 1999-06-15 Snow Brand Milk Prod Co Ltd 新規ベンゾイミダゾール誘導体
US6358930B1 (en) 1998-05-28 2002-03-19 Synsorb Biotech Inc. Treatment of C. difficile toxin B associated conditions
JP2000095767A (ja) 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
GB9908828D0 (en) 1999-04-16 1999-06-16 Univ Reading The Compounds
MXPA03004655A (es) 2000-11-27 2003-09-04 Ciba Sc Holding Ag Derivados 5-aril y 5-heteroaril-2-(2-hidroxifenil)-2h-benzotriazol substituidos como absorbentes de uv.
DE60139964D1 (de) 2000-12-15 2009-10-29 Vertex Pharma Bakterielle Gyrase-Hemmer sowie deren Verwendung
FR2819180B1 (fr) * 2001-01-11 2003-02-21 Oreal Composition photoprotectrices a base de polymeres amphiphiles d'au moins un monomere a insaturation ethylique a groupement sulfonique et comportant une partie hydrophobe
AU2002367953C1 (en) 2001-05-04 2009-02-19 Paratek Pharmaceuticals, Inc Transcription factor modulating compounds and methods of use thereof
IL161576A0 (en) 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
MXPA04012628A (es) 2002-06-13 2005-03-23 Patricia Olivershaffer DERIVADOS Y COMPUESTOS RELACIONADOS DEL áCIDO 2-UREIDO-6-HETEROARIL-3H-BENZOIMIDAZOL-4-CARBOXILICO COMO INHIBIDORES DE GIRASA Y/O TOPOISOMERASA IV PARA EL TRATAMIENTO DE INFECCIONES BACTERIALES.
WO2004041209A2 (en) 2002-11-01 2004-05-21 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
CA2562763A1 (en) 2004-04-23 2006-07-20 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
KR100629060B1 (ko) 2004-08-11 2006-09-26 주식회사 엘지화학 새로운 벤즈이미다졸계 화합물
US7528138B2 (en) 2004-11-04 2009-05-05 Vertex Pharmaceuticals Incorporated Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
CA2594665A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Thienopyrroles useful in the treatment of inflammation
US7825154B2 (en) 2005-08-12 2010-11-02 The United States Of America As Represented By The Secretary Of The Army Small molecule inhibitors of botulinum neurotoxins
EP1948635A1 (en) 2005-11-07 2008-07-30 Vertex Pharmaceuticals Incorporated Benzimidazole derivatives as gyrase inhibitors
KR100744827B1 (ko) * 2006-04-05 2007-08-01 한국화학연구원 트리플루오로비닐옥시기를 포함하는 불소계 벤즈이미다졸 단량체 및 이의 제조방법
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
CA2662074A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
PE20080888A1 (es) * 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
WO2008073451A2 (en) 2006-12-11 2008-06-19 Sirtris Pharmaceuticals, Inc. Benzoimidazole derivatives as sirtuin (sir) modulating compounds
JP2010513263A (ja) 2006-12-15 2010-04-30 ファイザー・プロダクツ・インク ベンズイミダゾール誘導体
JP5502076B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規化合物
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR101022649B1 (ko) 2008-08-07 2011-03-22 삼성모바일디스플레이주식회사 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치
GB0821913D0 (en) * 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
KR20130130875A (ko) 2009-02-27 2013-12-02 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염 바이러스 억제제
KR101219487B1 (ko) 2009-03-03 2013-01-15 덕산하이메탈(주) 비스벤조이미다졸 화합물 및 이를 이용한 유기전기소자, 그단말
PL2414369T3 (pl) 2009-04-02 2016-04-29 Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii Pochodne imidazo[2,1-b][1,3,4]tiadiazolu
US8536180B2 (en) 2009-05-27 2013-09-17 Abbvie Inc. Pyrimidine inhibitors of kinase activity
EP2435424B1 (en) 2009-05-29 2015-01-21 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
EP2443123B1 (en) 2009-06-15 2017-04-05 Rigel Pharmaceuticals, Inc. Small molecule inhibitors of spleen tyrosine kinase (syk)
WO2011046954A1 (en) 2009-10-13 2011-04-21 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses
WO2011151621A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3661849A (en) * 1965-10-06 1972-05-09 Ashland Oil Inc Heterocyclic polyimides prepared from heterocyclic diamines
US4087409A (en) * 1966-11-07 1978-05-02 Monsanto Company Ordered heterocyclic copolymers
JPS50154250A (enExample) * 1974-05-31 1975-12-12
US5317078A (en) * 1991-10-30 1994-05-31 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Polybenzimidazole via aromatic nucleophilic displacement
US5824698A (en) * 1994-11-17 1998-10-20 Hoffman-La Roche Inc. Antibacterial dibenzimidazole derivatives
WO2002060374A2 (en) * 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Benz-1,3-azole derivatives and their uses as heparanase inhibitors
WO2003007955A2 (en) * 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
EP1547996A1 (en) * 2002-08-30 2005-06-29 BF Research Institute, Inc. Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
Brand, R. A., et al, Journal of Polymer Science: Polymer Chemistry Edition, 1979, 17(4), 1145-52 *
CAS RN 228105-84-8, STN Entry Date 17 July 1999 *
CAS RN 450353-61-4, STN Entry Date 13 September 2002 *
CAS RN 518992-23-9, STN Entry Date 22 May 2003 *
Chaudhuri, P., et al, Journal of Organic Chemistry, 2007, 72(6), 1912-23 *
Chauvin, A. -S., et al, Chemistry - A Eurpoean Journal, 2007, 13(34), 9515-26 *
Hao, J. Y., et al, Synthetic Communications, 2003, 33(1), 79-86 *
Rigault, S., et al, Angewandte Chemie International Edition, 1998, 37(1/2), 169-72 *
Samsoniya, S., et al, Sakartvelos Mecnierebata Akademiis, Macne, 2003, 29(3-4), 222-4 *
Srivastava, R. P., et al, Indian Journal of Chemistry, Section B, 1993, 32B(10), 1035-44 *

Also Published As

Publication number Publication date
NZ593111A (en) 2013-05-31
US20160184283A1 (en) 2016-06-30
LT2907813T (lt) 2016-10-10
BRPI0922220A8 (pt) 2018-04-03
HRP20160597T1 (hr) 2016-09-23
EP2907813A1 (en) 2015-08-19
BRPI0922220A2 (pt) 2015-12-29
KR20110093925A (ko) 2011-08-18
BRPI0922220B8 (pt) 2021-05-25
SMT201500117B (it) 2015-07-09
EP3095783A1 (en) 2016-11-23
CY1116383T1 (el) 2017-02-08
ES2537059T3 (es) 2015-06-02
DK2373631T3 (en) 2015-05-26
IL213325A (en) 2016-02-29
MX2011005837A (es) 2011-11-18
RU2011127165A (ru) 2013-01-10
US8975416B2 (en) 2015-03-10
GB0821913D0 (en) 2009-01-07
SI2907813T1 (sl) 2016-09-30
IL213325A0 (en) 2011-07-31
SG171939A1 (en) 2011-07-28
BR122020013025B1 (pt) 2021-05-18
US9314456B2 (en) 2016-04-19
HK1208668A1 (en) 2016-03-11
EP2373631A2 (en) 2011-10-12
DK2907813T3 (en) 2016-07-25
US9763925B2 (en) 2017-09-19
CN102227411A (zh) 2011-10-26
ES2575908T3 (es) 2016-07-04
ZA201103751B (en) 2014-10-29
PT2907813T (pt) 2016-08-05
KR101643435B1 (ko) 2016-07-27
JP5665756B2 (ja) 2015-02-04
BRPI0922220B1 (pt) 2021-03-09
SMT201600259B (it) 2016-08-31
CN102227411B (zh) 2015-10-14
CA2744962A1 (en) 2010-06-10
PT2373631E (pt) 2015-06-09
WO2010063996A2 (en) 2010-06-10
HUE029151T2 (hu) 2017-02-28
US20150150861A1 (en) 2015-06-04
PL2907813T3 (pl) 2016-09-30
HK1162169A1 (en) 2012-08-24
EP2907813B1 (en) 2016-04-27
AU2009323854A2 (en) 2011-06-30
AU2009323854A1 (en) 2010-06-10
RS54904B1 (sr) 2016-10-31
CY1117934T1 (el) 2017-05-17
PL2373631T3 (pl) 2015-10-30
RU2525915C2 (ru) 2014-08-20
JP2015078220A (ja) 2015-04-23
SI2373631T1 (sl) 2015-08-31
CA2744962C (en) 2017-06-06
EP2373631B1 (en) 2015-02-25
JP2017048217A (ja) 2017-03-09
WO2010063996A3 (en) 2010-12-29
US20120020950A1 (en) 2012-01-26
HRP20150518T1 (hr) 2015-07-17
JP2012510458A (ja) 2012-05-10

Similar Documents

Publication Publication Date Title
AU2009323854B2 (en) Antibacterial compounds
US9278091B2 (en) Compounds for the treatment of Clostridium difficile associated disease
WO2011151618A2 (en) Compounds for the treatment of clostridium difficile-associated disease
WO2011151619A1 (en) Compounds for the treatment of clostridium difficile associated disease
WO2011151620A1 (en) Compounds for the treatment of clostridium difficile associated disease
HK1227868A1 (en) Antibacterial compositions
HK1227868A (en) Antibacterial compositions
WO2011151617A1 (en) Compounds for the treatment of clostridium difficile associated disease
HK1177706B (en) Compounds for the treatment of clostridium difficile associated disease

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 23 MAY 2011

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SUMMIT (OXFORD) LIMITED

Free format text: FORMER OWNER(S): SUMMIT CORPORATION PLC